NCT03232450View on ClinicalTrials.gov

Patent Foramen Ovale (PFO) Closure at the Time of Endovascular Cardiac Electronic Device Implantation

NAWithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 31, 2019

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Foramen Ovale, Patent
Interventions
DRUG

Aspirin

Subjects will receive 81 mg enteric coated aspirin

DEVICE

Cardiovascular Implantable Device (CIED)

All subjects will receive either a pacemaker, implantable cardioverter-defibrillator (ICD), or cardiac resynchronization therapy (CRT).

DEVICE

Gore Cardioform Septal Occluder

The Gore Cardioform Septal Occluder closes the patent foramen ovale (PFO).

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT03232450 - Patent Foramen Ovale (PFO) Closure at the Time of Endovascular Cardiac Electronic Device Implantation | Biotech Hunter | Biotech Hunter